ale.f02
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2023 (NCT05939947)
Timeline
Indications
Mechanism of action
- Claudin-18INHIBITOR
CLDN18 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06047171 | Phase 2 | Sep 7, 2023 | Alentis Therapeutics AG |
| NCT05939947 | Phase 1 | Apr 1, 2023 | Alentis Therapeutics AG |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alentis Therapeutics AG | For profit | 2 | 2 | 2 | 2023 |
1 organizations
Page 1 / 1